Weekly Digest – December 2025 Weekly Digest – December 2025 02 December 2025: MHRA approves Tisotumab vedotin for the treatment of cervical cancer The MHRA has approved Tisotumab vedotin (Tivdak) for adults with recurrent or metastatic cervical cancer whose disease […]
Weekly Digest – December 2025 Weekly Digest – December 2025 01 December 2025: European Medicines Agency validates Type II Variation Application for PADCEV (Enfortumab vedotin) with KEYTRUDA (Pembrolizumab) for certain patients with muscle-invasive bladder cancer The EMA has validated Astellas’ […]
Weekly Digest – December 2025 Weekly Digest – December 2025 04 December 2025: Celltrion’s ADC anticancer drug ‘CT-P70’ receives Fast Track Designation from the US FDA Celltrion’s ADC candidate CT-P70 has received FDA Fast Track Designation for metastatic non-squamous NSCLC […]
Weekly Digest – December 2025 Weekly Digest – December 2025 01 December 2025: IDEAYA Biosciences announces IND clearance for IDE034, a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC targeting multiple solid tumor types IDEAYA has received FDA IND clearance for IDE034, […]
Weekly Digest – December 2025 Weekly Digest – December 2025 04 December 2025: Kelun-Biotech and Crescent Biopharma announce strategic partnership to develop and commercialize novel oncology therapeutics Kelun-Biotech and Crescent Biopharma have entered a strategic partnership to co-develop and commercialize […]
Weekly Digest – December 2025 Weekly Digest – December 2025 03 December 2025: SK Biopharm secures European actinium‑225 supply from Germany’s Eckert & Ziegler SK Biopharm has signed an agreement with Germany’s Eckert & Ziegler to secure a reliable supply […]
Weekly Digest – November 2025 Weekly Digest – November 2025 25 November 2025: U.S. FDA approves PADCEV plus Keytruda for certain patients with bladder cancer The FDA has approved PADCEV (enfortumab vedotin-ejfv) plus Keytruda as the first perioperative regimen to […]
Weekly Digest – November 2025 Weekly Digest – November 2025 24 November 2025: Blenrep approved in Australia for use in adults with relapsed or refractory multiple myeloma as part of triplet combination therapy Australia has approved Blenrep (belantamab mafodotin), a first-of-its-kind […]
Weekly Digest – November 2025 Weekly Digest – November 2025 24 November 2025: Sichuan Biokin Pharmaceutical announces acceptance of the New Drug Application for Iza-Bren (an EGFR×HER3 Bispecific ADC) for the treatment of locally advanced or metastatic nasopharyngeal carcinoma China’s […]
Weekly Digest – November 2025 Weekly Digest – November 2025 24 November 2025: Avenzo Therapeutics granted Fast Track Designation for AVZO-103, a potential best-in-class nectin4/TROP2 bispecific ADC, for the treatment of patients with urothelial cancer previously treated with enfortumab vedotin […]
